Related Experiment Video
Updated: Jul 31, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Development of Tumor Markers for Breast Cancer Immunotherapy
Qianqian Fang1, Guoshuang Shen1, Qiqi Xie1
1Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, 810000, China.
Abstract:
Although breast cancer treatment has been developed remarkably in recent years, it remains the primary cause of death among women. Immune checkpoint blockade therapy has significantly altered the way breast cancer is treated, although not all patients benefit from the changes. At present, the most effective mechanism of immune checkpoint blockade application in malignant tumors is not clear and efficacy may be influenced by many factors, including host, tumor, and tumor microenvironment dynamics. Therefore, there is a pressing need for tumor immunomarkers that can be used to screen patients and help determine which of them would benefit from breast cancer immunotherapy. At present, no single tumor marker can predict treatment efficacy with sufficient accuracy. Multiple markers may be combined to more accurately pinpoint patients who will respond favorably to immune checkpoint blockade medication. In this review, we have examined the breast cancer treatments, developments in research on the role of tumor markers in maximizing the clinical efficacy of immune checkpoint inhibitors, prospects for the identification of novel therapeutic targets, and the creation of individualized treatment plans. We also discuss how tumor markers can provide guidance for clinical practice.
Insights
Identifying effective breast cancer immunotherapy requires better patient selection. Novel tumor immunomarkers are crucial for predicting response to immune checkpoint blockade therapy and guiding personalized treatment plans.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Breast cancer remains a leading cause of death in women despite treatment advancements.
- Immune checkpoint blockade therapy shows promise but lacks universal efficacy.
- Predicting patient response to immunotherapy is challenging due to complex biological factors.
Purpose of the Study:
- To review current breast cancer treatments and the role of tumor markers in immunotherapy.
- To explore the potential of novel therapeutic targets for personalized treatment.
- To discuss how tumor markers can guide clinical practice in immunotherapy.
Main Methods:
- Literature review of breast cancer treatments and immunomarker research.
- Analysis of factors influencing immune checkpoint inhibitor efficacy.
- Examination of strategies for identifying predictive biomarkers.
Main Results:
- No single tumor marker accurately predicts response to immune checkpoint blockade.
- Combination of multiple markers may improve patient stratification.
- Tumor microenvironment and host factors significantly influence treatment outcomes.
Conclusions:
- Development of accurate tumor immunomarkers is essential for optimizing breast cancer immunotherapy.
- Personalized treatment plans based on biomarker profiles are needed.
- Further research into novel therapeutic targets and biomarker combinations is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...